YU-SHAN HUANGHSIN-YUN SUNSUI-YUAN CHANGYU-CHUNG CHUANGARISTINE CHENGHuang S.-H.YI-CHIA HUANGChen G.-J.KUAN-YIN LINSu Y.-C.Liu W.-C.CHIEN-CHING HUNG2020-06-182020-06-1820191936-0533https://scholars.lib.ntu.edu.tw/handle/123456789/503479Background: Data regarding the durability of HBV viral suppression with combination antiretroviral therapy (cART) containing tenofovir disoproxil fumarate (TDF) combined with lamivudine (3TC) or emtricitabine (FTC) in HIV/HBV-coinfected patients are scarce in hyperendemic areas of chronic HBV infection. Methods: Between 2004 and 2016, HIV/HBV-coinfected Taiwanese with available baseline HBV DNA load were retrospectively reviewed. Determinations of plasma HBV DNA load, HBV serologic markers (HBsAg, anti-HBs, HBeAg, and anti-HBe), and liver function were performed after initiation of cART. Factors associated with time to undetectable HBV DNA load were explored. Results: A total of 366 patients were included according to cART history: Group 1, 3TC as the only anti-HBV therapy (n = 73); Group 2, TDF-containing cART as initial therapy (n = 127); and Group 3, switch of 3TC-based to TDF-containing cART (n = 166). At year 5, HBV suppression was achieved in 77.8%, 95.7%, and 95.7% of Groups 1, 2 and 3, respectively. In multivariate Cox regression analysis, TDF (± 3TC or FTC) but not 3TC alone as initial anti-HBV therapy was significantly associated with HBV suppression (adjusted hazard ratio [aHR] 2.635; 95% CI 1.720–4.037), while HBeAg positivity at baseline was associated with failure to achieve HBV suppression (aHR 0.293; 95% CI 0.178–0.482). Loss of HBsAg occurred in 15 patients (4.1%), with 7 (1.9%) seroconversion to anti-HBs positivity, while HBeAg seroconversion occurred in 11 (16.9%) of 65 HBeAg-positive patients. Conclusions: TDF-containing cART achieved durable HBV viral suppression in HIV/HBV-coinfected patients and HBeAg positivity at baseline was associated with failure to achieve HBV suppression despite long-term TDF-containing cART. ? 2019, Asian Pacific Association for the Study of the Liver.[SDGs]SDG3emtricitabine; hepatitis B surface antigen; hepatitis B(e) antigen; lamivudine; tenofovir disoproxil; antivirus agent; lamivudine; tenofovir; virus DNA; adult; Article; chronic hepatitis B; controlled study; enzyme immunoassay; female; follow up; hazard ratio; Hepatitis B virus; human; Human immunodeficiency virus infection; liver function; major clinical study; male; mixed infection; nonhuman; observational study; population research; priority journal; protein blood level; retrospective study; seroconversion; Taiwan; Taiwanese; treatment response; virus load; chronic hepatitis B; combination drug therapy; drug substitution; Human immunodeficiency virus infection; metabolism; treatment outcome; Adult; Antiviral Agents; DNA, Viral; Drug Substitution; Drug Therapy, Combination; Female; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Loadjournal article10.1007/s12072-019-09953-4311775052-s2.0-85067264753